GlassScriptPhysician profile
Jennifer Cheng
NPI 1699975037
$11,589.11
in general payments reported to CMS, 2019-2025
52 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $519 · 2021: $647 · 2022: $1,739 · 2023: $2,932 · 2024: $2,312 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,868 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,868.40 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,723.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,199.13 | 2019-2025 | Korlym |
| Lilly USA, LLC | $875.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $702.00 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $699.18 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $564.97 | 2019-2025 | |
| Mannkind Corporation | $558.42 | 2020-2025 | Afrezza |
| Embecta Corp. | $516.53 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.38 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $407.58 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $308.11 | 2019-2023 | Farxiga |
| Abbvie INC. | $305.78 | 2023-2025 | Synthroid |
| Medtronic, INC. | $295.57 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Pfizer INC. | $292.07 | 2019-2025 | |
| Dexcom, INC. | $285.74 | 2023-2025 | Dexcom G6 Transmitter |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.